Treatment of severe, refractory pyoderma gangrenosum with infliximab, adalimumab and intravenous immunoglobulin-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment of severe, refractory pyoderma gangrenosum with infliximab, adalimumab and intravenous immunoglobulin

Published:2023-04-27 Issue:3 Volume:64 Page:433-435
ISSN:0004-8380
Container-title:Australasian Journal of Dermatology
language:en
Short-container-title:Aust J Dermatology

Author:

Holmes Zachary¹^ORCID,Nguyen Jacqueline¹^ORCID,Courtney Ashling²,Jobson Dale¹²^ORCID,Kelly Robert¹

Affiliation:

1. St Vincent's Hospital Fitzroy Victoria Australia

2. Monash University Clayton Victoria Australia

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajd.14067

Reference10 articles.

1. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial

2. Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Final analysis of a 52‐week phase 3 open‐label study

3. Biologics and immunoglobulins in the treatment of pyoderma gangrenosum – analysis of 52 patients;Herberger K;J Dtsch Dermatol Ges,2018

4. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi‐systematic review

5. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pyoderma gangrenosum in Takayasu arteritis;Joint Bone Spine;2024-07

2. Adalimumab;Reactions Weekly;2023-10-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP